Selected article for: "effective vaccine development and human human"
Author: Du, Lanying; Tai, Wanbo; Zhou, Yusen; Jiang, Shibo
Title: Vaccines for the prevention against the threat of MERS-CoV
  • Cord-id: eji6dw94
  • Document date: 2016_4_6
    • ID: eji6dw94
    Snippet: First identified in 2012, Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is listed as a new Category C Priority Pathogen. While the high mortality of MERS-CoV infection is further intensified by potential human-to-human transmissibility, no MERS vaccines are available for human use. This review explains immune responses resulting from MERS-CoV infection, describes MERS vaccine criteria, and presents available small animal models to evaluate the efficacy of MERS vaccines. Current
    Document: First identified in 2012, Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is listed as a new Category C Priority Pathogen. While the high mortality of MERS-CoV infection is further intensified by potential human-to-human transmissibility, no MERS vaccines are available for human use. This review explains immune responses resulting from MERS-CoV infection, describes MERS vaccine criteria, and presents available small animal models to evaluate the efficacy of MERS vaccines. Current advances in vaccine development are summarized, focusing on specific applications and limitations of each vaccine category. Taken together, this review provides valuable guidelines toward the development of an effective and safe MERS vaccine. This article is written for a Special Focus Issue of Expert Review of Vaccines on “Vaccines for Biodefence”.

    Search related documents:
    Co phrase search for related documents
    • activation capable and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and ad adenovirus: 1
    • acute sars cov respiratory syndrome coronavirus and addition essential: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and adjuvant absence: 1
    • acute sars cov respiratory syndrome coronavirus and adjuvant presence: 1, 2
    • acute sars cov respiratory syndrome coronavirus and low dosage: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and low respiratory tract: 1, 2, 3, 4, 5